Align Technology, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Align Technology, Inc. trades at $182.04 (market cap $12.86B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.17. The key difference: Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | VWO | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | — |
52-Week High | $207.19 | $61.24 |
52-Week Low | $124.88 | $49.54 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
VWO trades at $59.89, up 0.67% today, with a bullish technical signal from moving averages. The ETF offers broad emerging markets exposure with a low 0.06% expense ratio and a 2.4% dividend yield. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exclusion of South Korean stocks due to index methodology.
The outlook for VWO is supported by diversification benefits and attractive valuations in emerging markets, but risks include geopolitical tensions and index composition gaps. Analyst sentiment is mixed, with performance heavily influenced by regional allocations and macroeconomic trends.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →